What Is Matrixyl 3000? The Peptide Behind the “Plumper Skin” Claims

If you’ve spent any time on the back of skincare bottles, you’ve seen Matrixyl 3000. It’s on serums at every price tier — $20 supermarket bottles, $200 prestige treatments, and most of what’s between. The marketing language is usually some variant of “plumper skin, smoother lines, visibly firmer.” What’s underneath the marketing is a real ingredient with one of the deepest published research files in cosmetic chemistry — and an exact concentration story you can read off an ingredient list if you know what to look for.

This is the longer version. Who made Matrixyl 3000, what the research actually shows, what concentration to look for, and where it earns its place in a routine.

The basics: what’s actually in the bottle

Matrixyl 3000 is a trade name. The actual ingredients you’ll see on an INCI list are a pair of palmitoylated peptides:

• Palmitoyl tetrapeptide-7 (sometimes written as palmitoyl oligopeptide-7)
• Palmitoyl tripeptide-1 (sometimes written as palmitoyl oligopeptide)

Both are signal peptides — short amino acid chains the skin recognises as fragments of broken-down extracellular matrix proteins. The “palmitoyl-” prefix is a fatty acid attached to the peptide so it can move through the lipid layer of the skin and reach the cells that respond to those signals.

The two peptides work in tandem. Palmitoyl tripeptide-1 is associated with the appearance of plumper skin; palmitoyl tetrapeptide-7 is associated with the look of less obvious redness around fine lines. Together they sit in the “matrikine” category — peptide fragments that act like messengers in the skin’s natural turnover process.

Who developed it and when

Matrixyl 3000 was developed by Sederma, a French specialty-actives company owned by Croda. Sederma also developed the original Matrixyl (palmitoyl pentapeptide-4) in the late 1990s, and the newer Matrixyl synthe’6 (palmitoyl tripeptide-38) in the 2010s.

Matrixyl 3000 launched commercially in the early 2000s. Croda / Sederma have published a series of in-vitro and small-scale clinical studies on it over the past two decades — those papers are the source of most of the marketing language you see across skincare brands. They are the original research, but they are also Sederma’s own studies. That matters for context: they are not independent peer-review on every brand’s specific finished product.

This is the line every honest peptide brand has to walk. The ingredient research is real. The brand cannot extend that research to “our specific 30 ml bottle is clinically proven” without doing its own clinical trial on its own finished formula. We don’t make that claim on Aperture Skin products, and we’d encourage you to read other brands sceptically when they do.

What the published research actually shows

Sederma’s published work on Matrixyl 3000 reports outcomes related to:

• The appearance of fine lines and the visible texture of skin over 8–12 weeks of consistent use
• The look of more uniform tone over the same period
• A subjective sense of skin “feeling” firmer (graded by participant self-assessment)

A few important caveats on what those papers don’t say:

They do not show Matrixyl 3000 stimulating, boosting, or increasing collagen production in a regulated, measurable, in-vivo human sense. The headline mechanism is described as “modulating fibroblast activity” in vitro — laboratory cell cultures, not living skin. Brands that translate that into “boosts collagen by 350%” are stretching the in-vitro number into a claim it doesn’t carry.

They do not establish a single, approved therapeutic outcome. Matrixyl 3000 is a cosmetic ingredient. Anywhere in the world, marketing it as a treatment for a disease or physiological condition crosses the line into therapeutic-goods territory.

What the research does support is the cautious “appearance of” language you see on well-regulated brands’ bottles. That’s a real, defensible claim — and most of what people experience after 8–12 weeks of consistent use lines up with it.

How to find Matrixyl 3000 on an ingredient list

Look for both of these as a pair:

• Palmitoyl tetrapeptide-7 (or palmitoyl oligopeptide-7)
• Palmitoyl tripeptide-1 (or palmitoyl oligopeptide)

If only one of the two is present, the product isn’t using the Matrixyl 3000 trade complex — it’s using a single related peptide. That isn’t bad, but the brand shouldn’t be calling it Matrixyl 3000 specifically.

Their position on the INCI list tells you whether you’re looking at a meaningful dose. Sederma’s recommended use level for Matrixyl 3000 is roughly 3–8% of the finished formula. If both peptides appear before the preservative (commonly phenoxyethanol), the formula is likely above the 1% threshold and probably in the meaningful range. If they appear after the preservative — among the colour additives and fragrance — they’re being added at trace concentrations.

A few brands publish the exact percentage on the bottle. Those are the easy ones to evaluate. Most don’t, which is when the INCI position becomes your best signal.

Concentrations: meaningful vs marketing

Cosmetic chemistry has a concept called “fairy-dusting” — adding an ingredient at a concentration low enough that it can be listed on the front of the bottle, but too low to do what the front of the bottle implies. Matrixyl 3000 is one of the most commonly fairy-dusted peptides in the industry, because the name has marketing weight.

A reasonable test before you buy:

If the price is under $25 AUD and Matrixyl 3000 is the headline ingredient, scrutinise the INCI list. A real 3–8% dose costs the brand more in raw materials than that price band usually allows for.

If the brand can’t tell you the percentage at all — not on the bottle, not on the website, not by email — assume fairy dust until proven otherwise.

If the named peptides appear after a long list of fillers (silicones, alcohol, fragrance, colourants), the concentration is likely below the dose Sederma’s research used.

The Aperture Skin take

Peptide Serum 01 uses Matrixyl 3000 in the upper half of its formula, paired with Argireline (acetyl hexapeptide-8) and palmitoyl tripeptide-1 as supporting peptides. The full INCI list is published on the product page — no hidden ratios.

We picked Matrixyl 3000 over newer or trendier peptide complexes because the published file is the deepest of any cosmetic peptide we evaluated. We’re not in the business of being first to market with experimental ingredients. We use the boring, well-researched ones at sensible doses, in formulas designed to be tolerated nightly.

For the longer scientific version, see The Science page.

Further reading

• The Complete Guide to Peptides in Skincare (2026)
• GHK-Cu Copper Peptide: 50 Years of Research, Explained
• How to Read a Skincare Ingredient List (And What Brands Hide)

---

This article is general information, not personalised skincare advice. Aperture Skin products are cosmetics intended to support the appearance of healthy-looking skin. They are not therapeutic goods and are not intended to treat, cure, or prevent any condition.